MedTrace Logo

An Investigational Drug Study In Patients With COPD (Chronic Obstructive Pulmonary Disease) (MK-0873-005)

NCT00132730 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 604

Last updated 2018-10-12

Study results available
· View outcomes & findings →

Summary

This is a study to evaluate the effectiveness and tolerability of a once-daily oral medication (MK-0873) for the treatment of COPD (chronic obstructive pulmonary disease) to determine whether the study drug leads to an improvement in pulmonary (lung) function, as well as symptoms, and quality of life.

Conditions

  • Lung Diseases
  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

MK-0873 2.5 mg

DRUG

MK-0873 1.25 mg

DRUG

MK-0873 0.75 mg

DRUG

Placebo to MK-0873

DRUG

Usual Care

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-01
Primary Completion
2005-08-17
Completion
2005-08-17

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00132730 on ClinicalTrials.gov